Federal Register of Legislation - Australian Government

Skip to primary navigation Skip to primary content
Federal Register of Legislation Skip to Content
SearchOpen search

Primary content

Bookmark

this version | go to latest

National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 9)

Authoritative Version
  • - F2022L01413
  • No longer in force
PB 104 of 2022 Determinations/Health as made
This instrument amends the National Health (Listed Drugs on F1 or F2) Determination 2021 by adding three new drugs, burosumab, cemiplimab and tepotinib, to F1.
Administered by: Health and Aged Care
Registered 31 Oct 2022
Tabling HistoryDate
Tabled HR07-Nov-2022
Tabled Senate21-Nov-2022
Date of repeal 08 Mar 2023
Repealed by Division 1 of Part 3 of Chapter 3 of the Legislation Act 2003
Table of contents.
Skip Navigation Links.

Commonwealth Coat of Arms of Australia

 

PB 104 of 2022

 

National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 9)

I, Nikolai Tsyganov, Acting Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health and Aged Care, delegate of the Minister for Health and Aged Care, make the following determination.

Dated               28 October 2022                     

NIKOLAI TSYGANOV

Acting Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health and Aged Care

 

 

Contents

1  Name........................................................................................................................................ 1

2  Commencement........................................................................................................................ 1

3  Authority.................................................................................................................................. 1

4  Schedules................................................................................................................................. 1

Schedule 1—Amendments                                                                                           2

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)                2

 

 

1  Name

                   This instrument is the National Health (Listed Drugs on F1 or F2) Amendment Determination 2022 (No. 9).

                   This instrument may also be cited as PB 104 of 2022.

2  Commencement

             (1)  Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

 

Commencement information

Column 1

Column 2

Column 3

Provisions

Commencement

Date/Details

1.  The whole of this instrument

1 November 2022.

 

Note:          This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.

             (2)  Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3  Authority

                   This instrument is made under subsection 85AB(1) of the National Health Act 1953.

4  Schedules

                   Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments

National Health (Listed Drugs on F1 or F2) Determination 2021 (PB 33 of 2021)

1     Schedule 1, after item dealing with Budesonide

insert:

Burosumab     

2     Schedule 1, after item dealing with Carmustine

insert:

Cemiplimab

3     Schedule 1, after item dealing with Tenofovir alafenamide with emtricitabine, elvitegravir and cobicistat

insert:

Tepotinib